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ABSTRACT
Objective: To describe the characteristics of women seeking treatment for
symptoms of stress urinary incontinence (SUI) and to investigate the
association of SUI symptoms with generic health-related quality of life
(HRQoL) as measured by the EuroQol (EQ-5D) instrument.
Methods: The Stress Urinary Incontinence Treatment (SUIT) study was a
12-month observational study in four European countries that evaluated
the cost-effectiveness of duloxetine compared with other forms of nonsur-
gical intervention in the treatment of the symptoms of SUI. Four hundred
thirty-one physicians observed women seeking treatment for their SUI, and
recorded the care provided and the outcomes of that care at enrollment
and at 3, 6 and 12 months afterward The impact of SUI on baseline
HRQoL as expressed by the EQ-5D index score was assessed by linear and
logistic regression.
Results: Three thousand seven hundred sixty-two women were enrolled
into SUIT, with the largest patient group from Germany. Overall, the
majority of women were postmenopausal, had a mean age of 58.0 years,
were not current smokers, and tended to be overweight (mean body mass
index [BMI] = 27.7 kg/m2), with at least one comorbidity. The health state
index scores were signiﬁcantly and independently inﬂuenced by the pres-
ence of comorbidity(ies) affecting quality of life, total number of stress and
urge incontinence episodes, urinary incontinence subtype, comorbidi-
ty(ies) affecting incontinence, BMI, socioeconomic status, educational
status, age, and country.
Conclusion: This article describes the characteristics of patients at the
SUIT enrollment visit, and demonstrates that the number of incontinence
episodes has a signiﬁcant impact on the EQ-5D index score.
Keywords: EQ-5D, outcomes research, patient-reported outcomes,
women’s health.
Introduction
Urinary incontinence (UI), or the “involuntary leakage of urine”
[1], affects between 10% and 60% of women worldwide [2–6]
and can be categorized as either stress UI (SUI), which is the
involuntary leakage of urine upon exertion, sneezing or cough-
ing; or urge UI (UUI), which is the involuntary leakage of urine
accompanied by, or immediately preceded by, urgency. Both
symptoms are present in women with mixed UI (MUI) [1]. Pure
SUI accounts for approximately half of all UI in adult women
[2,3,5].
Initial management of SUI is recommended in general prac-
tice using conservative treatments, including lifestyle interven-
tions and pelvic ﬂoor muscle training [7]. The prospective
urinary incontinence research (PURE) study [8] was the ﬁrst
European study to investigate the economic and self-assessed
impact of UI. The PURE baseline data showed that many women
with symptoms of SUI were receiving off-label medications,
including anticholinergics, tricyclic antidepressants, and estro-
gens, or no pharmaceutical treatment at all [9]. These drugs show
limited evidence of efﬁcacy in SUI, and some have signiﬁcant side
effects [10]. Duloxetine is the ﬁrst drug approved in Europe to
treat women with moderate to severe SUI. The safety and efﬁcacy
of duloxetine were globally assessed in large randomized clinical
trials [11–15].
Economic considerations are increasingly important in
health-care decision-making [16]. The Stress Urinary Inconti-
nence Treatment (SUIT) study, a 12-month observational study
undertaken in four European countries, was designed with the
primary objective of evaluating the “real-life” cost-effectiveness
of duloxetine compared with other forms of nonsurgical
intervention.
The primary effectiveness measure to be used in this cost-
effectiveness evaluation is the quality adjusted life year (QALY).
A QALY can be calculated from a health-related quality of life
(HRQoL) index score (“utilities”) derived from patients’
responses to the EuroQol (EQ-5D) instrument [17].
This article presents baseline data describing the characteris-
tics of the patients enrolled in the SUIT study, as well as an
analysis undertaken to investigate the association between base-
line patient characteristics and EQ-5D index scores. In particular,
the association between the severity of UI symptoms and the
EQ-5D index score is of interest to establish that this HRQoL
measure is sensitive to changes in the severity of incontinence
symptoms.
Methods
Study Design
SUIT was a longitudinal, observational, multicenter, 12-month
study conducted in Germany, the UK, Sweden, and Ireland to
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evaluate the cost-effectiveness of duloxetine compared with other
forms of nonsurgical intervention in the outpatient treatment of
the symptoms of SUI in females. The outcomes and direct costs
associated with any medical treatment of SUI were secondary
objectives.
Women aged 18 years or over were eligible if they: 1) were
suffering from SUI symptoms (with or without urge symptoms)
according to the clinical opinion of the investigator; 2) presented
during the normal course of care; 3) had been under treatment or
were seeking treatment for SUI, and 4) initiated or changed (i.e.,
switched or added on) SUI treatment at the time of the enroll-
ment visit.
The questionnaires were in local languages, in which partici-
pants had to be competent. Participants were excluded if they
were pregnant or had been in the preceding 6 months, were
concurrently participating in another study that included an
investigational drug or procedure, or were awaiting surgery for
SUI. To ensure a representative sample of treatment-seeking
women was enrolled, the participants were identiﬁed during the
course of a routinely occurring visit. The initiation or change of
SUI treatment was at the investigator’s discretion during the
normal course of care, and enrollment only took place after the
decision to initiate or change treatment had been made.
The study was approved by the local ethics committees
and/or review boards of each participating center. A written
informed consent was obtained from each patient and from each
investigator.
Data Collection
The care provided and outcomes of that care were recorded at
enrollment, and 3, 6 and 12 months afterward. The data
recorded at the ﬁrst observation included demographic charac-
teristics, medical and UI history, and 12 months of retrospective
data on health-care resource utilization for SUI treatment.
The impact of SUI on HRQoL was assessed using the EQ-5D
instrument [17], which is composed of ﬁve domains of health
(mobility, self-care, usual activities, pain/discomfort, anxiety/
depression), each rated by the patient on a three-point scale: “no
problems,” “some/moderate problems,” and “extreme prob-
lems.” Complete sets of ﬁve responses generated up to 243
possible sequences, each mapped to a health state index
(“utility”) to provide a summary value across all domains where
the scale runs from 0 (equivalent to death) to 1 (equivalent to full
health). Negative values were possible [17]. EQ-5D has been
validated in 36 ofﬁcial languages. For the purposes of this study,
an EQ-5D index based on an algorithm derived using time trade-
off values from a sample of the UK public was employed [17,18]
and compared with UK population norms [19].
Incontinence episode frequencies were captured using the
two-item stress and urge incontinence questionnaire (S/UIQ)
[20], which relies on a recall of the number of UI episodes
experienced during the preceding week. Women were classiﬁed
into relevant UI subtype groups according to the S/UIQ answers:
“stress episodes and no urge episodes” was classiﬁed as pure SUI,
“urge episodes and no stress episodes” as pure UUI, and “1 or
more stress episodes and 1 or more urge episodes” as MUI.
Patients with two zeroes (indicating no stress or urge episodes) or
missing data for either question (133 patients, or 3.6% of the
total) were excluded from the analyses.
All study documents were prepared in English and translated
into the local country languages, with back translation to ensure
homogeneity, and validation by native-speaking local clinical
experts. Patient questionnaires were provided in each relevant,
ofﬁcially available language version from the EQ-5D group [21]
and the Medical Outcomes Trust [22]. Key data ﬁelds in the data
collection forms (DCFs) were checked for completeness, and data
were then forwarded for entry into the electronic study database.
Analysis
A statistical analysis plan and rules for handling incomplete and
implausible data were ﬁnalized before database lock. All analyses
were conducted in SAS® 8.2 (SAS Institute Inc, Cary, NC). An
“enrolled” patient was one who was entered into the study and
provided DCFs for entry into the database, and patients were
“eligible for analysis” if their DCF showed that they fulﬁlled the
inclusion criteria.
Categorical data were summarized by counts and percent-
ages, and continuous variables by means, standard deviations,
medians, minima and maxima, lower and upper quartiles, and
95% conﬁdence limits as appropriate.
The baseline characteristics and EQ-5D index scores of
enrolled patients are presented by country in Tables 1 to 4 and
compared using analysis of variance for continuous variables and
Fisher’s exact tests for binary variables. Because of the observa-
tional nature of this study, it is probable that there were many
confounding factors leading to the differences observed between
the countries so the results of the statistical tests should be
interpreted with caution.
The EQ-5D index scores showed a non-normal distribution,
with 35% of the patients having a perfect score of 1. Although
the mean and median scores were similar, the distribution had a
long tail toward the lower values, although at the upper end of
the distribution, a large percentage of perfect scores was
observed. Hence, a multivariate logistic regression was per-
formed, with a binary dependent variable of whether an EQ-5D
index score of 1 or less than 1 was recorded, and all demographic
characteristics, disease severity, and medical history variables
collected at the baseline observation as the independent variables
in the full model. The effect of removing variables was investi-
gated using backward elimination methods until a reduced model
containing only statistically signiﬁcantly (P  0.05) independent
variables was obtained. Correlations between pairs of indepen-
dent variables were calculated to test for collinearity.
To test the sensitivity of the results to the choice of analysis
method and to the statistical distribution of the EQ-5D index
scores, a multivariate linear regression was also performed using
the actual EQ-5D health state index scores (rather than the
binary dependent variable) and the same set of independent
variables as for the logistic regression.
Results
Demographic and Clinical Characteristics
A total of 3762 women were enrolled in the study between April
7, 2005 and February 28, 2006 in Germany, Ireland, Sweden,
and the UK. Four hundred thirty-one investigating physicians
participated, including primary care physicians (PCPs), gynecolo-
gists, urologists, and geriatricians/others. Eighty-two percent of
the investigators in Germany and 69% in Sweden were gynecolo-
gists, whereas all of the investigators in Ireland and 98% in the
UK were PCPs. Germany was the only country where urologists
participated, accounting for 15% of the German investigators.
A total of 3739 women were eligible for analysis (over 99%
of the enrolled number). The patients’ baseline characteristics are
presented in Table 1. Two-thirds of the women were postmeno-
pausal. The differences in the level of education between
the countries are evident: most participating women from
Germany, Ireland, and the UK were not educated above the local
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mandatory level, although in Sweden, two-thirds of the partici-
pants had a further or university education. A few of the women
were current smokers, although more than half of the patients in
Sweden and the UK had smoked in the past. The SUIT partici-
pants tended to be overweight, with a mean body mass index of
27.7 kg/m2. Most of the patients had at least one concurrent
medical condition, most commonly hypertension. For most of
the women, the ﬁrst observation in SUIT was not their ﬁrst
consultation for UI. MUI was more common than SUI (Table 2)
in all countries except Sweden where SUI was more common.
Most women were not receiving ongoing drug therapy for SUI
symptoms at baseline; conservative treatment for SUI symptoms
was more common in all countries, particularly in Sweden.
Differences in the frequency of the stress leakage episodes
were noted between SUI and MUI in all four countries (Table 3)
with women with SUI having fewer episodes per week than
women with MUI. The women in Ireland typically experienced
fewer stress leakage episodes per week for both SUI and MUI
than women in the other three countries.
EQ-5D
Of the ﬁve domains of the EQ-5D health state proﬁle, the
patients’ pain/discomfort was most affected, although their self-
care was least affected (Fig. 1). The patients’ EQ-5D index scores
are shown in Table 4.
The ﬁnal logistic regression model for the health score index
included 3346 (89%) patients with complete data and had a
Hosmer and Lemeshow goodness of ﬁt chi-square statistic of
5.443 (8 df, P = 0.709), suggesting an adequate ﬁt of the model
to the data. The single variable with the most missing data was
the UI subtype, with data missing for 3.6% of patients. Age and
socioeconomic status were the most strongly correlated pair of
independent variables (r = 0.54), with older patients less likely to
be participating in the workforce and also more likely to have
comorbidities (r = 0.24 for comorbidities affecting incontinence
and r = 0.31 for those affecting QOL). Previous surgery for UI
was also correlated with having comorbidities affecting inconti-
nence (r = 0.24), as were being in the workforce and having a
further/university education (r = 0.27). All of these variables
were still included in the full model.
The variables statistically signiﬁcantly associated with the
EQ-5D index score included in the ﬁnal model are shown in
Table 5. Each additional stress and urge episode per week was
associated with a decrease in the odds of having an EQ-5D index
score of 1 of 0.986, although each comorbidity affecting HRQoL
was associated with a reduction in the odds of having a perfect
EQ-5D index score by a factor of 0.524. Each comorbidity
affecting incontinence was associated with a reduction in the
odds of having a perfect EQ-5D index score by a factor of 0.726.
There appeared to be a relationship between better health state
and socioeconomic status, and a higher health status among
women with SUI only. The effect of country is also signiﬁcant.
The estimates reﬂect the observed differences between the coun-
tries in the raw data for EQ-5D health state score.
Among the independent variables included in the linear
regression model with 3381 patients (90%), their relative impor-
tance and the direction of the effect estimates were very similar to
those found in the logistic regression, indicating that the models
Table 2 Proportions of urinary incontinence (UI) symptoms and ongoing treatment by country
All Germany Ireland Sweden UK P-value*
Type of UI by symptoms (%)†
SUI 37.2 35.7 31.4 51.7 33.3
MUI 61.5 63.1 68.6 47.0 64.4 P < 0.0001
Patients with any ongoing medication for SUI symptoms (%) 18.0 18.2 25.9 21.2 13.0 P < 0.001
Patients with any ongoing conservative treatment for SUI symptoms (%)‡ 36.1 31.6 35.5 54.8 41.2 P < 0.0001
*Fisher’s exact tests removing UUI responses for type of UI.
†Type by S/UIQ.
‡Includes lifestyle interventions, bladder diary, all forms of pelvic ﬂoor exercises.
MUI, mixed urinary incontinence; S/UIQ, stress and urge incontinence questionnaire; SUI, stress urinary incontinence; UUI, urge urinary incontinence.
Table 3 Leakage episodes by country and UI type by S/UIQ
Country
Distribution of leakage episode frequency
S/UIQ stress
Mean (SD) IEF/week
S/UIQ urge
Mean (SD) IEF/week
Germany
SUI 12.8 (13.9) —
MUI 16.8 (14.1) 8.0 (9.3)
All* 15.0 (14.2) 5.1 (8.5)
UK
SUI 10.2 (12.8) —
MUI 15.4 (16.1) 7.8 (9.4)
All 13.1 (15.2) 5.0 (8.4)
Ireland
SUI 7.3 (13.5) —
MUI 9.7 (10.0) 6.7 (8.8)
All 8.8 (11.2) 4.5 (7.9)
Sweden
SUI 11.4 (14.3) —
MUI 14.5 (16.1) 6.8 (8.2)
All 12.3 (15.1) 3.2 (6.6)
P-value† P < 0.0001 P < 0.0001
*“All” includes patients classiﬁed as UUI.
†Analysis of variance between countries, all UI types.
IEF, incontinence episode frequencies; MUI, mixed urinary incontinence; S/UIQ, stress and
urge incontinence questionnaire; SUI, stress urinary incontinence; UI, urinary incontinence.
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are fairly robust to the deviation of the health state index score
from the normal distribution.
Discussion
The aim of this article is to present the baseline characteristics of
patients enrolled in the SUIT study and to describe the associa-
tion of these characteristics with EQ-5D index scores. In particu-
lar, it was important to understand the association of the severity
of incontinence symptoms with EQ-5D index score before per-
forming the planned economic evaluation using the longitudinal
study data.
The logistic regression analysis of the association between the
patients’ baseline characteristics and the patients’ EQ-5D index
scores showed that the scores declined with increased frequency
of incontinence episodes. With each additional weekly stress or
urge episode, there was a decrease in the odds of having an index
score of 1 of 0.986. Thus, an increase of one incontinence
episode per day would decrease the odds of a perfect health state
score by 0.908 times. This is consistent with other studies that
have shown increasing severity of incontinence to be negatively
correlated with quality of life [23,24]. The analysis also showed
that the subtype of UI was important, with MUI impacting more
greatly on the EQ-5D index score than SUI. This is also consis-
tent with the results from other studies [23,24].
The EQ-5D index scores declined with the presence of comor-
bidities that affect HRQoL and UI. Each comorbidity affecting
HRQoL was associated with a reduction in the odds of having a
score of 1 of 0.524, although each comorbidity directly affecting
incontinence was associated with a smaller reduction by a factor
of 0.726.
The relationship between incontinence and signiﬁcant comor-
bidity, and their adverse effect upon HRQoL, is likely to be
complex. Some of the conditions we deﬁned as having an effect
Table 4 EQ-5D index
Mean (SD) HSI Median HSI N P-value*
Country P < 0.0001
Germany 0.80 (0.22) 0.80 2557
Ireland 0.89 (0.15) 1.00 107
Sweden 0.80 (0.23) 0.80 466
UK 0.73 (0.29) 0.80 553
Total IEF P < 0.0001
7 per week or less 0.86 (0.18) 0.85 996
7 to 13 per week 0.81 (0.21) 0.80 760
14 per week or more 0.74 (0.26) 0.80 1856
Socioeconomic status P < 0.0001
In workforce 0.85 (0.19) 0.85 1449
Other 0.75 (0.25) 0.80 2230
Comorbidity affecting HRQoL P < 0.0001
No 0.86 (0.19) 0.85 1510
Yes 0.74 (0.25) 0.80 2104
Comorbidity affecting UI P < 0.0001
No 0.82 (0.22) 0.85 1984
Yes 0.75 (0.25) 0.80 1651
Previous surgery P = 0.012
No 0.79 (0.24) 0.80 3287
Yes 0.76 (0.24) 0.80 380
UI subtype P < 0.0001
Mixed SUI/UUI 0.75 (0.25) 0.80 2181
Pure SUI 0.85 (0.20) 0.85 1325
Pure UUI 0.81 (0.18) 0.80 49
*Analysis of variance.
HRQoL, health-related quality of life; HSI, Health State Index; IEF, incontinence episode frequencies; SUI, stress urinary incontinence; UI, urinary incontinence; UUI, urge urinary incontinence.
Table 5 Adjusted odds ratios for EQ-5D index (in order of strength of association of variables—multivariate logistic regression)
Variable*
Adjusted† odds ratios with 95% CI Wald chi-square
value P-valueEstimate 95% CI
Comorbidity(ies) affecting HRQoL (reference: none) 0.524 0.446 0.614 62.9 P < 0.0001
Total number of stress & urge episodes 0.986 0.981 0.991 30.3 P < 0.0001
Pure SUI (reference mixed SUI/UUI) 1.563 1.326 1.841 29.7 P < 0.0001
Comorbidity(ies) affecting incontinence (reference: none) 0.726 0.620 0.851 15.6 P < 0.0001
BMI (kg/m2) 0.972 0.957 0.988 12.1 P < 0.001
Participating in the workforce (reference: Socioeconomic status other) 1.341 1.115 1.614 9.7 P = 0.002
Further/university education (reference: no/mandatory education) 0.830 0.705 0.977 5.0 P = 0.025
Age (years) 0.992 0.985 1.000 4.4 P = 0.036
Country (reference UK) 18.1 P < 0.001
Sweden 1.183 0.874 1.602
Ireland 2.489 1.557 3.981
Germany 1.392 1.113 1.741
*Estimated intercept value is 0.8647 with a standard error of 0.3460, a Wald chi-square value of 6.2448, and a P-value of 0.0125.
†Factor by which the odds of having a score of 1 on the EQ-5D index changes with each increase of 1 unit for continuous variables (e.g., number of episodes) or between the speciﬁed levels
of categorical variables.
BMI, body mass index; CI, conﬁdence interval; HRQoL, health-related quality of life; SUI, stress urinary incontinence; UUI, urge urinary incontinence.
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on HRQoL rather than incontinence may, in actual fact, have an
inﬂuence upon both. Nevertheless, these ﬁgures help to compare
the magnitude of the impact of incontinence episodes and differ-
ent comorbidities on HRQoL, and to demonstrate that inconti-
nence is a signiﬁcant disturber of well-being.
This observational study included a heterogeneous sample of
investigators and patients in the different countries. The ﬁrst step
in analyzing the data was therefore to summarize the patient and
investigator characteristics. The investigators with different spe-
cialities were represented in differing proportions in the partici-
pating countries. Our data could not conﬁrm whether the types
of investigators in SUIT are representative of the delivery of UI
treatment in the respective countries. In many European coun-
tries, both PCPs and gynecologists provide initial UI care; in
Germany, urologists also have a role [25]. In the UK, however,
most women will be initially treated by PCPs [26].
Despite the heterogeneous patient and investigator sample,
there was a striking concordance of patient characteristics across
the recruiting countries. The mean age of the women was 58.0
years, two-thirds were postmenopausal, and two-thirds were not
participating in the workforce. The majority of the women
tended to be overweight, and most had at least one comorbidity.
In accordance with the general population data [27], most of the
women in SUIT were not current smokers. The women in
Sweden appeared different from those of the other countries,
with a higher proportion of participants who were employed,
were ex-smokers, and had received further education, although
only a lower proportion with current comorbidities.
Symptoms varied between countries; SUI and MUI were
roughly equally prevalent in Sweden unlike the other countries.
The women in Ireland typically experienced fewer leakage epi-
sodes per week for both SUI and MUI than women in the other
three countries. They also had higher median EQ-5D index
scores, indicating a higher HRQoL. The relative prevalence of
MUI compared with pure SUI is comparable with that from other
large-scale community-based studies [5].
The women enrolled in the study reported lower EQ-5D
health state index scores than the general female population in
Germany, Sweden, and the UK [19]. There is no population norm
data available for Ireland.
In the logistic regression analysis, the impact of country on
the EQ-5D index score reﬂects the observed differences between
the countries in the raw data. Country, however, should be
regarded more as a known source of variation than as a predic-
tor. The rate of self-reported problems with EQ-5D is known to
be highly variable between countries as the EQ-5D data from 15
different countries demonstrate [19]. Cross-country differences
exist in EQ-5D results even after population data are standard-
ized for demographic differences.
This study and the data it generated have certain limitations.
Although the observational nature of the study intentionally
allowed the enrollment of a heterogeneous sample of any female
patient seeking treatment for SUI rather than a highly selected
patient population as enrolled in clinical trials, this presents
challenges with regard to the analysis and interpretation of the
study data. The observed differences may be due to unobserved
confounding factors and can therefore only be described rather
than explained. The goodness-of-ﬁt of the model may also be
affected by unobserved factors that inﬂuenced the EQ-5D index
scores. The UK EQ-5D utility weights were used for all patients,
although most of the study population came from other
countries.
In summary, this article describes the characteristics of
women seeking treatment for SUI symptoms and provides a
unique snapshot of incontinent women in different European
countries. This analysis of the baseline data demonstrates that
the number of incontinence episodes has a signiﬁcant impact on
the EQ-5D index score, which gives us conﬁdence in using it as
the effectiveness measure for the cost-effectiveness analysis that
will be performed on the 12-month longitudinal study data from
SUIT.
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